HRP20150588T1 - Parazitocidni spojevi dihidroizoksazola - Google Patents

Parazitocidni spojevi dihidroizoksazola Download PDF

Info

Publication number
HRP20150588T1
HRP20150588T1 HRP20150588TT HRP20150588T HRP20150588T1 HR P20150588 T1 HRP20150588 T1 HR P20150588T1 HR P20150588T T HRP20150588T T HR P20150588TT HR P20150588 T HRP20150588 T HR P20150588T HR P20150588 T1 HRP20150588 T1 HR P20150588T1
Authority
HR
Croatia
Prior art keywords
trifluoromethyl
dihydroisoxazol
thiophene
carboxamide
tetrahydrobenzo
Prior art date
Application number
HRP20150588TT
Other languages
English (en)
Inventor
Zengyun AN
Liang Chen
Shuhui Chen
Jean Marie Defauw
Scott Dale HOLMSTROM
Ping Hu
Chongzhi TANG
William Hunter White
Wentao Wu
Yang Zhang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20150588T1 publication Critical patent/HRP20150588T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (15)

1. Spoj, ili njegova sol, formule I [image] , naznačen time što A je [image] ; n je 0 ili 1; R1 je tienil ili fenil, gdje je navedeni tienil ili fenil supstituiran s 2 ili 3 ista ili različita atoma halogena; R2 je svaki put neovisno vodik, C1-C5 alkil, C3-C6 cikloalkil ili C1-C5 haloagenlkil; R3 je [image] ; p je svaki put neovisno 0 ili 1; R4 je C1-C5 alkil, C1-C5 haloagenlkil, C1-C5 cijanoalkil, C1-C5 alkiltio, C3-C6 cikloalkil, izborno supstituiran s hidroksi, halogenom ili C1-C5 alkilom; C3-C5 cikloheteroalkil, izborno supstituiran s C1-C5 alkilom, C3-C6 cikloalkilom ili C1-C5 haloagenlkilom; fenil, tienil, piridinil ili [image] , gdje jedan od ugljika u navedenim cikloalkilima, neovisno, ili u cikloheteroalkilu, može tvoriti karbonilnu skupinu, te gdje je navedeni fenil, tienil ili piridinil izborno supstituiran s halogenom ili karbamoilnom skupinom; R5 je hidroksi, -O-(C1-C5 alkil) ili [image] ; R6 je vodik, C1-C5 alkil, C1-C5 haloagenlkil, C1-C5 cijanoalkil, C1-C5 alkiltio ili C2-C5 alkinil; ili se R2 i R3 kombinira kako bi, s dušikom na kojeg su vezani, tvorili [image] ; Y1, Y2 i Y3 su ugljik ili dušik, gdje je najviše samo jedan od Y1, Y2 i Y3 dušik, a kada je Y1, Y2 ili Y3 je ugljik, svaki od njih može biti supstituiran s C1-C5 alkilom; R7 je vodik, halogen, C1-C5 alkil ili [image] ; R8 je hidroksi, -O-(C1-C5 alkil) ili [image] ; R9 je C1-C5 alkil, [image] ; i R10 je vodik, C1-C5 alkil, C1-C5 haloagenlkil, C1-C5 cijanoalkil, C1-C5 alkiltio ili C2-C5 alkinil.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što je A [image] , te što je R2 vodik, a n je 1.
3. Spoj u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, ili njegova sol, naznačen time što je R3 [image] [image] [image] [image] [image] [image] [image] .
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što je A [image] , te što je Y1 dušik.
5. Spoj u skladu s patentnim zahtjevom 4, ili njegova sol, naznačen time što je R7 [image] [image] [image] ili [image] .
6. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što je 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N,N-dimetil-2-(4-{3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil}piperazin-1-il)acetamid; metilni ester ({3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil}amino)octene kiseline; metilni ester ({3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil}amino)octene kiseline; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(3-oksocikloheksil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; [2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il]amid 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-((R)-2-oksopirolidin-3-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-okso-2-(prop-2-inilamino)etil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-((R)-2-oksopirolidin-3-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-okso-2-(prop-2-inilamino)etil)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-(etilamino)-2-oksoetil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((tetrahidrofuran-2-il)metil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-(metiltio)etil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(3,3,3-trifluorpropil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(3-hidroksicikloheksil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(5-fluorpiridin-2-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(tetrahidro-2H-piran-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(tietan-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(1-ciklopropil-2-oksopirolidin-3-il)-3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-okso-2-(prop-2-inilamino)etil)-3-(5-(3,4,5-triklortiofen-2-il)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(tetrahidro-2H-piran-4-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(1-ciklopropil-2-oksopirolidin-3-il)-3-(5-(3,4,5-triklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(4-oksocikloheksil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(1-ciklopropil-2-oksopirolidin-3-il)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(4-oksocikloheksil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-1-(2,2,2-trifluoretil)pirolidin-3-il)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-((R)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-((S)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(4-karbamoilfenil)-3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; (3-karbamoiltiofen-2-il)amid 3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; 2-(3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamido)octena kiselina; ({3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil}amino)octena kiselina; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; N-(2-(cijanometilamino)-2-oksoetil)-3-(5-(3,4,5-triklortiofen-2-il)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksamid; (S)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; [(2,2-difluoretilkarbamoil)metil]amid 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; [(2-fluoretilkarbamoil)metil]amid 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; [(2-fluoretilkarbamoil)metil]amid (S)-3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; 3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; (S)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid; 3-(4-klorbenzo[b]tiofen-2-il)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol; 2-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]tieno[2,3-c]piridin; 5-brom-2-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]tieno[2,3-b]piridin; 2-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]tieno[2,3-b]piridin; 3-(benzo[b]tiofen-2-il)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol; 3-(benzo[d]thiazol-2-il)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol; 5-(3,5-diklorfenil)-3-(3-metilbenzo[b]tiofen-2-il)-5-(trifluormetil)-4,5-dihidroizoksazol; 5-(3,5-diklorfenil)-3-(5-metilbenzo[b]tiofen-2-il)-5-(trifluormetil)-4,5-dihidroizoksazol; 3-(5-klorbenzo[b]tiofen-2-il)-5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol; metil-2-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)tieno[2,3-b]piridin-5-karboksilat; 2-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]tieno[2,3-b]piridin-5-karboksilna kiselina; 2-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(2,2,2-trifluoretilamino)etil)tieno[2,3-b]piridin-5-karboksamid; ili 2-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-((R)-2-oksopirolidin-3-il)tieno[2,3-b]piridin-5-karboksamid.
7. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što je [(2,2-difluoretilkarbamoil)metil]amid) (S)-3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline.
8. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što je (S)-3-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-N-(2-okso-2-(prop-2-inilamino)etil)-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksamid.
9. Spoj, naznačen time što je (1,1-dioksotietan-3-il)amid 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; (1,1-dioksoheksahidro-116-tiopiran-4-il)amid 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; (1,1-dioksoheksahidrotiopiran-4-il)amid 3-[5-(3,4,5-triklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; (1,1-dioksotietan-3-il)amid 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; (1,1-dioksoheksahidrotiopiran-4-il)amid 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; ili njihove soli.
10. Formulacija, naznačena time što sadrži spoj, ili njegovu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 9, kao i jednu ili više prihvatljivih podloga.
11. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u kontroli infestacije parazitima u ili na životinji.
12. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je navedena životinja pas ili mačka, a navedeni parazit je krpelj.
13. Spoj Formule II, ili njegova sol, [image] , naznačen time što n je 0 ili 1; R1 je tienil ili fenil, gdje je navedeni tienil ili fenil supstituiran s 2 ili 3 ista ili različita atoma halogena; i R11 je hidroksi, -O-(C1-C4 alkil) ili atom halogena.
14. Spoj u skladu s patentnim zahtjevom 13, naznačen time što je metilni ester 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; metilni ester 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; metilni ester 3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; metilni ester 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilne kiseline; metilni ester 3-[5-(3,4,5-triklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; metilni ester 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilne kiseline; 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilna kiselina; 3-[5-(3,5-diklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilna kiselina; 3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilna kiselina; 3-[5-(3,4,5-triklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilna kiselina; 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karboksilna kiselina; 3-[5-(3,5-diklor-4-fluorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilna kiselina; 3-[5-(3,4,5-triklorfenil)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-5,6-dihidro-4H-ciklopenta[c]tiofen-1-karboksilna kiselina; 3-(5-(3,5-diklorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil-klorid; ili 3-[5-(3,4,5-triklortiofen-2-il)-5-trifluormetil-4,5-dihidroizoksazol-3-il]-4,5,6,7-tetrahidrobenzo[c]tiofen-1-karbonil-klorid.
15. Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u reakciji spoja u skladu s patentnim zahtjevom 13 ili 14 sa spojem formule [image] .
HRP20150588TT 2011-05-19 2015-06-02 Parazitocidni spojevi dihidroizoksazola HRP20150588T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2011/074294 WO2012155352A1 (en) 2011-05-19 2011-05-19 Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
PCT/CN2012/072878 WO2012155676A1 (en) 2011-05-19 2012-03-23 Parasiticidal compounds, methods, and formulations
PCT/US2012/036883 WO2012158396A1 (en) 2011-05-19 2012-05-08 Parasiticidal dihydroisoxazole compounds
EP20120721146 EP2710000B1 (en) 2011-05-19 2012-05-08 Parasiticidal dihydroisoxazole compounds

Publications (1)

Publication Number Publication Date
HRP20150588T1 true HRP20150588T1 (hr) 2015-07-03

Family

ID=47176150

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150588TT HRP20150588T1 (hr) 2011-05-19 2015-06-02 Parazitocidni spojevi dihidroizoksazola

Country Status (30)

Country Link
US (3) US8648081B2 (hr)
EP (2) EP2918583A1 (hr)
JP (1) JP5989099B2 (hr)
KR (1) KR101586553B1 (hr)
CN (1) CN103547576B (hr)
AR (1) AR086296A1 (hr)
AU (1) AU2012256220B2 (hr)
BR (1) BR112013028132B1 (hr)
CA (1) CA2835436C (hr)
CL (1) CL2013003287A1 (hr)
CO (1) CO6811873A2 (hr)
CR (1) CR20130486A (hr)
CY (1) CY1116450T1 (hr)
DK (1) DK2710000T3 (hr)
EA (1) EA023711B1 (hr)
ES (1) ES2543392T3 (hr)
HK (1) HK1191337A1 (hr)
HR (1) HRP20150588T1 (hr)
IL (1) IL229007A (hr)
ME (1) ME02113B (hr)
MX (1) MX341739B (hr)
PE (1) PE20141041A1 (hr)
PL (1) PL2710000T3 (hr)
PT (1) PT2710000E (hr)
RS (1) RS54048B1 (hr)
SG (1) SG194836A1 (hr)
SI (1) SI2710000T1 (hr)
TW (1) TWI554508B (hr)
UA (1) UA110519C2 (hr)
WO (3) WO2012155352A1 (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33403A (es) * 2010-06-17 2011-12-30 Novartis Ag Compuestos orgánicos con novedosas isoxazolinas, sus n-óxidos, s-óxidos y sales
WO2012155352A1 (en) 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
EP2931696B1 (en) 2012-12-11 2018-08-22 Bracco Imaging S.p.A Continuous process for the preparation of (s)-2-acetyloxypropionic acid
BR112015018311B1 (pt) 2013-02-06 2021-01-05 Bayer Animal Health Gmbh compostos derivados de pirazol substituídos por halogêneo como agentes de controle de pragas, composição farmacêutica e uso dos mesmos, processo para a preparação de composições de proteção de colheitas e método para o controle de pragas
BR112016017527B1 (pt) 2014-01-03 2021-01-05 Bayer Animal Health Gmbh compostos, usos de compostos, composições farmacêuticas, processo para produzir composições e método não terapêutico para controlar pragas
US9884876B2 (en) 2014-05-09 2018-02-06 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
HUE049284T2 (hu) * 2014-06-10 2020-09-28 Bracco Imaging Spa Eljárás (S)-2-acetiloxipropionsav és származékai elõállítására
WO2016008830A1 (de) 2014-07-15 2016-01-21 Bayer Cropscience Aktiengesellschaft Aryl-triazolyl-pyridine als schädlingsbekämpfungsmittel
BR112017027855B1 (pt) 2015-06-23 2022-11-16 Intervet International B.V. Composição farmacêutica, seu uso, água potável medicamentosa e método para sua preparação
CN109328017A (zh) * 2016-05-10 2019-02-12 瑞士伊兰科动物保健有限公司 用于控制海虱的二氢异噁唑化合物
WO2018081733A1 (en) * 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission
EP3573978A1 (en) 2017-01-25 2019-12-04 Basf Se Process for preparation of benzylic amides
WO2018166855A1 (en) * 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
AR113997A1 (es) 2017-12-21 2020-07-08 Intervet Int Bv Composiciones antiparasitarias para unción dorsal continua
MX2021004995A (es) * 2018-10-29 2021-06-15 Basf Se Proceso para la preparacion de compuestos de aldol opticamente enriquecidos.
CN114901275A (zh) 2019-12-20 2022-08-12 纳米医疗有限公司 可用于治疗癌症的含有Toll样受体(“TLR”)激动剂前药的配制和/或共同配制的脂质体组合物及其方法
JP2024511956A (ja) * 2021-03-11 2024-03-18 イン ザ ボウル アニマル ヘルス，インコーポレーテッド 経口のイヌ科動物の飼料およびイヌ科動物におけるダニの侵入を制御する方法
CN117412673A (zh) * 2021-03-11 2024-01-16 碗中动物健康公司 犬科动物口服饲料和在犬科动物中控制蚤侵袭的方法
KR20240016325A (ko) * 2021-06-02 2024-02-06 에프엠씨 코포레이션 무척추동물 해충을 방제하기 위한 융합된 피리딘
CA3224226A1 (en) * 2021-06-25 2022-12-29 In The Bowl Animal Health, Inc. Oral feline feed and methods for controlling tick infestations in a feline
CN117915782A (zh) * 2021-06-25 2024-04-19 碗中动物健康公司 猫科动物口服饲料和在猫科动物中控制蚤侵袭的方法
CN114085159B (zh) * 2021-11-25 2023-04-07 浙江大学 一种1,3-环己二酮还原胺化制备3-氨基环己酮的方法
WO2023208447A1 (en) 2022-04-25 2023-11-02 Basf Se An emulsifiable concentrate having a (substituted) benzaldehyde-based solvent system
EP4342885A1 (en) 2022-09-20 2024-03-27 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005219788B2 (en) * 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
HUP0501170A2 (en) 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
TWI412322B (zh) * 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
JP2008044880A (ja) * 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
RU2009141185A (ru) 2007-04-10 2011-05-20 Байер КропСайенс АГ (DE) Инсектицидные производные арилизоксазолина
JP5473906B2 (ja) * 2007-06-13 2014-04-16 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー イソキサゾリン殺虫剤
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
CN102088856B (zh) 2008-07-09 2015-11-25 巴斯夫欧洲公司 包含异*唑啉化合物的杀虫活性混合物i
NZ590756A (en) * 2008-09-04 2013-01-25 Syngenta Participations Ag Insecticidal compounds
CA2747060A1 (en) * 2008-12-18 2010-07-15 Novartis Ag Isoxazolines derivatives and their use as pesticide
AR074790A1 (es) 2008-12-19 2011-02-09 Novartis Ag Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
JP2011098956A (ja) * 2009-10-09 2011-05-19 Sumitomo Chemical Co Ltd イソオキサゾリン化合物及びその用途
WO2011073098A1 (de) * 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
JP5409968B2 (ja) 2010-08-05 2014-02-05 ゾエティス・エルエルシー 駆虫剤としてのイソオキサゾリン誘導体
EP2619189B1 (en) * 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
JP2014505089A (ja) * 2011-02-10 2014-02-27 ノバルティス アーゲー 無脊椎有害動物を防除するためのイソオキサゾリン誘導体
WO2012155352A1 (en) 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof

Also Published As

Publication number Publication date
ES2543392T3 (es) 2015-08-18
PL2710000T3 (pl) 2015-10-30
CR20130486A (es) 2014-03-12
WO2012155676A1 (en) 2012-11-22
CN103547576B (zh) 2016-06-08
AU2012256220B2 (en) 2016-12-15
WO2012158396A1 (en) 2012-11-22
RS54048B1 (en) 2015-10-30
EP2918583A1 (en) 2015-09-16
US8648081B2 (en) 2014-02-11
MX2013013446A (es) 2014-07-14
CL2013003287A1 (es) 2014-07-25
EP2710000A1 (en) 2014-03-26
KR20140002054A (ko) 2014-01-07
AR086296A1 (es) 2013-12-04
CA2835436C (en) 2015-12-22
ME02113B (me) 2015-10-20
PT2710000E (pt) 2015-07-06
WO2012155352A1 (en) 2012-11-22
IL229007A (en) 2016-07-31
CY1116450T1 (el) 2017-02-08
US9255111B2 (en) 2016-02-09
TWI554508B (zh) 2016-10-21
IL229007A0 (en) 2013-12-31
KR101586553B1 (ko) 2016-01-18
EA023711B1 (ru) 2016-07-29
UA110519C2 (uk) 2016-01-12
SG194836A1 (en) 2013-12-30
JP2014515347A (ja) 2014-06-30
EP2710000B1 (en) 2015-04-29
US20150072993A1 (en) 2015-03-12
HK1191337A1 (en) 2014-07-25
AU2012256220A1 (en) 2013-10-10
US8889710B2 (en) 2014-11-18
BR112013028132A2 (pt) 2016-08-09
US20130217699A1 (en) 2013-08-22
DK2710000T3 (en) 2015-05-26
US20140107149A1 (en) 2014-04-17
TW201307337A (zh) 2013-02-16
EA201391542A1 (ru) 2014-03-31
PE20141041A1 (es) 2014-08-27
NZ616409A (en) 2015-11-27
BR112013028132B1 (pt) 2021-05-04
MX341739B (es) 2016-08-31
SI2710000T1 (sl) 2015-06-30
JP5989099B2 (ja) 2016-09-07
CA2835436A1 (en) 2012-11-22
CN103547576A (zh) 2014-01-29
CO6811873A2 (es) 2013-12-16

Similar Documents

Publication Publication Date Title
HRP20150588T1 (hr) Parazitocidni spojevi dihidroizoksazola
NZ600922A (en) Anti parasitic dihydroazole compounds and compositions comprising same
JP2013501720A5 (hr)
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
HRP20200781T1 (hr) DERIVATI PIRAZOLO[1,5-a]PIRAZIN-4-ILA KAO INHIBITORI JAK
HRP20190728T1 (hr) Derivati aminobenzamida kao učinkovita sredstva za kontrolu životinjskih parazita
JP6440625B2 (ja) 精神分裂病を処置するための方法および組成物
HRP20140503T1 (hr) Derivati tieno-piridina kao inhibitori mek
JP2017160233A5 (hr)
HRP20140295T1 (hr) Azetidinil diamidi kao inhibitori monoacilglicerol lipaze
HRP20160355T1 (hr) Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
HRP20170317T1 (hr) Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
HRP20130143T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
NZ601656A (en) Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease
TW200710086A (en) Diaryl-substituted hetero 5-membered ring derivatives
RU2018103198A (ru) Новые соединения циклического n-карбоксамида, применяемые в качестве гербицидов
JP2012525431A5 (hr)
AR045083A1 (es) Productos aril-heteroaromaticos, composiciones que los contienen y utilizacion como medicamento
JP2013539789A5 (hr)
EA201591240A1 (ru) Композиции {3-[5-(4-хлорфенил)-1h-пирроло[2,3-b]пиридин-3-карбонил]-2,4-дифторфенил}амида пропан-1-сульфоновой кислоты и их применение
CA2510519A1 (en) Condensed furan compounds
MX2010009284A (es) Composicion para uso agricola para controlar o prevenir enfermedades vegetales provocadas por patogenos vegetales.
CA2615466A1 (en) Benzofused five-membered heterocycles as inhibitors of catechol-o-methyltransferase (comt) enzyme